Mingina Tulantched, Zhao Min
Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang 11004, PR China.
Biomark Med. 2018 May;12(5):419-425. doi: 10.2217/bmm-2018-0013. Epub 2018 Apr 26.
Biomarkers are molecules measured in plasma, serum or other body fluids to characterize a disease. PARK7 and NDKA roles in the management of stroke are still on study. Therefore, their potentials need to be developed in totality. The aim of this review is to demonstrate that PARK7 and NDKA could present more clinical important information as biomarkers for management of stroke disease. Main contents: Four main aspects of PARK7 and NDKA are exploited in this review. First, their diagnostic value is discussed in order to demonstrate their possible role as stroke diagnosis markers. Second, this article will exploit the correlation of both markers with time, by showing their dynamic changes in serum and plasma. Third, it describes the observed relationship of their levels with NIH Stroke Scale. The last aspect visits the possibility of their implementation in stroke therapy.
This article explores recent findings and proposes the potential roles that PARK7 and NDKA play in the management of acute stroke disease.
生物标志物是在血浆、血清或其他体液中检测的分子，用于表征疾病。PARK7和NDKA在中风管理中的作用仍在研究中。因此，它们的潜力需要全面开发。本综述的目的是证明PARK7和NDKA作为中风疾病管理的生物标志物可能提供更多临床重要信息。
本综述探讨了PARK7和NDKA的四个主要方面。首先，讨论它们的诊断价值，以证明它们作为中风诊断标志物的可能作用。其次，本文将通过展示它们在血清和血浆中的动态变化来探讨这两种标志物与时间的相关性。第三，描述观察到的它们的水平与美国国立卫生研究院中风量表的关系。最后一个方面探讨它们在中风治疗中应用的可能性。
本文探讨了近期的研究结果，并提出了PARK7和NDKA在急性中风疾病管理中所起的潜在作用。
